Ironwood Pharmaceuticals, Inc. (IRWD) Receives $17.56 Consensus Price Target from Analysts
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has received an average rating of “Hold” from the fourteen research firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $17.56.
IRWD has been the subject of several analyst reports. Credit Suisse Group initiated coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, November 27th. They set a “buy” rating and a $19.00 price target for the company. Zacks Investment Research upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, January 18th. Morgan Stanley reiterated a “hold” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 4th. ValuEngine upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 29th. Finally, BidaskClub cut shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th.
In related news, insider Mark G. Currie sold 60,000 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $15.45, for a total transaction of $927,000.00. Following the transaction, the insider now owns 835,000 shares of the company’s stock, valued at approximately $12,900,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Peter M. Hecht sold 113,405 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the transaction, the chief executive officer now directly owns 4,696,917 shares in the company, valued at approximately $71,017,385.04. The disclosure for this sale can be found here. In the last quarter, insiders have sold 174,905 shares of company stock valued at $2,666,359. 7.63% of the stock is owned by corporate insiders.
Ironwood Pharmaceuticals (NASDAQ IRWD) traded up $0.06 on Friday, reaching $13.73. 1,649,300 shares of the company’s stock traded hands, compared to its average volume of 1,930,050. The company has a quick ratio of 4.86, a current ratio of 4.87 and a debt-to-equity ratio of -22.31. The firm has a market cap of $2,056.14, a PE ratio of -14.15 and a beta of 1.29. Ironwood Pharmaceuticals has a 52-week low of $12.89 and a 52-week high of $19.94.
ILLEGAL ACTIVITY NOTICE: “Ironwood Pharmaceuticals, Inc. (IRWD) Receives $17.56 Consensus Price Target from Analysts” was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/ironwood-pharmaceuticals-inc-irwd-receives-17-56-consensus-price-target-from-analysts/1861770.html.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.